Want to see SE:ELIC full AI Analyst Report?

Elicera Therapeutics AB (ELIC) Price & Analysis

3 Followers

ELIC Stock Chart & Stats

kr5.35

kr0.03(1.27%)

At close: Mar 06 4:00 PM EST

kr5.35

kr0.03(1.27%)

Day’s Range― - ―

52-Week Rangekr2.25 - kr8.21

Previous CloseN/A

Volume204.65K

Average Volume (3M)476.63K

Market Cap

kr198.54M

Enterprise Valuekr84.26

Total Cash (Recent Filing)kr58.13M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.20

Next Earnings

Nov 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding66,736,374

10 Day Avg. Volume271,059

30 Day Avg. Volume476,629

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)10.19

Price to Sales (P/S)0.00

P/FCF Ratio-11.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.42

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA debt-free balance sheet reduces financial risk and avoids interest or refinancing burdens while the company advances its development programs. This gives management greater flexibility in allocating capital toward research, clinical work, and potential partnering activities over the next several quarters.

Meaningful Capital BaseThe substantial equity base provides a stronger financial foundation than a highly leveraged structure and may support continued development activity. Although losses are reducing that base, the current capital position remains a durable offset to balance-sheet risk during the company’s clinical-stage phase.

Platform-led Partnering ModelElicera’s iTANK platform and engineered immunotherapy programs create multiple potential routes to value creation through licensing, co-development, or acquisition transactions. If development milestones are achieved, this model could provide non-product revenue opportunities and broaden commercialization resources.

Bears Say

No Current TTM RevenueRevenue has deteriorated sharply to zero on a trailing basis, indicating that the company currently lacks a commercial revenue stream to fund operations. Until partnering proceeds, product sales, or development milestones emerge, financial performance remains highly dependent on successful pipeline advancement.

Persistent Sizable LossesLarge recurring operating and net losses show that the present business model has not yet reached profitability. Continued losses can consume equity, limit internally funded investment, and increase the importance of successful clinical development or external transactions to establish sustainable earnings.

Sustained Cash BurnHeavy negative operating and free cash flow indicates that ongoing research and development require substantial funding without current cash generation. The declining free-cash-flow trend increases execution and financing pressure, particularly because recurring product revenue has not yet been established.

ELIC FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was kr2.25 and its highest was kr8.21 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is kr198.54M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Nov 27, 2026 which is in 71 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Aug 28, 2026. The company reported -kr0.117 earnings per share for the quarter.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 66,736,374 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -kr0.117 in its last earnings report. Following the earnings report the stock price went up 10.68%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in SE:ELIC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.